Evidence map›Paper›PMID 34123305›Full record

ArticleChemical science2020

Coordinating bioorthogonal reactions with two tumor-microenvironment-responsive nanovehicles for spatiotemporally controlled prodrug activation.

Liping Zuo, Jingjing Ding, Changkun Li, Feng Lin, Peng R Chen, Peilin Wang, Guihong Lu, Jinfeng Zhang, Li-Li Huang, Hai-Yan Xie

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Spatiotemporally controlled OChemical science · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Liping ZuoSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.
Jingjing DingSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.
Changkun LiShimadzu (China) Co., Ltd Beijing Branch Beijing 100020 PR China.
Feng LinPeking-Tsinghua Center for Life Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University Beijing 100871 China.
Peng R ChenPeking-Tsinghua Center for Life Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University Beijing 100871 China.ORCID https://orcid.org/0000-0002-0402-7417
Peilin WangSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.
Guihong LuSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.
Jinfeng ZhangSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.
Li-Li HuangSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.ORCID https://orcid.org/0000-0002-0007-4427
Hai-Yan XieSchool of Life Science, Beijing Institute of Technology No. 5 South Zhong Guan Cun Street Beijing 100081 China hyanxie@bit.edu.cn.ORCID https://orcid.org/0000-0002-6330-7929
Beijing Institute of Technology · CNPeking University · CNShimadzu (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precise activation of prodrugs in tumor tissues is critical to ensuring specific antitumor efficacy, meanwhile reducing the serious adverse effects. Here, a spatiotemporally controlled prodrug activation strategy was provided by integrating the inverse electron demand Diels-Alder (IEDDA) reaction with two tumor-microenvironment-responsive nanovehicles. The prodrug (Dox-TCO) and [4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl]methanamine (Tz) were separately camouflaged into low pH and matrix metalloproteinase 2 (MMP-2) sensitive micellar nanoparticles. After systemic administration, only in the tumor tissues could both the nanovehicles dissociate

Identifiers

PMID34123305
PMCPMC8150104
OpenAlexW2999157714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.